Recent research have focused on the overlap of GLP-1|GIP|GCGR agonist therapies and dopaminergic signaling. While GIP agonists are commonly employed for treating type 2 diabetes, their potential consequences on reward circuits, specifically mediated by DA networks, are attracting substantial interest. This report presents a concise examination of c